Chase Yarbrough

Chase Yarbrough

Auto-generated profile, based on publicly available information

Chase Yarbrough

Faculty of Medicine, Harvard Medical School , Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2024 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
CYChase Yarbrough
Chase Yarbrough
MMMichael Miller
Michael Miller
MZMosala Zulu
Mosala Zulu
DSDanielle Sharp
Danielle Sharp
AAAfom Tesfalem Andom
Afom Tesfalem Andom
PSPaul Sonenthal
Paul Sonenthal
The burden of long-term functional impairment following curative treatment for tuberculosis (TB) constitutes a significant global health problem. By some estimates, chronic respiratory impairment, or post-tuberculosis lung disease (PTLD), is present in just over half of all patients who have completed TB therapy. Despite this high prevalence and substantial associated morbidity, discussion of PTLD is essentially absent from international and national TB policies and guidelines. Clear and ambitious clinical standards should be established for the diagnosis and management of PTLD, including the stipulation that all patients completing TB therapy should be screened for PTLD. Patients diagnosed with PTLD should receive linkage to chronic care, with access to inhalers and home oxygen, as indicated based on individual symptoms and pathophysiology. Leveraging their considerable influence, major funders, such as The Global Fund, could help close the gap in PTLD care by including PTLD in their strategic vision and funding streams. Immediate action is needed to address the substantial burden of disease associated with PTLD. This will require expanding the global approach to TB to include a commitment to diagnosing and treating long-term complications following initial curative therapy.

31 May 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
AEAhmed D Elnaiem
Ahmed D Elnaiem
ACAnand B Chukka
Anand B Chukka
CSCynthia M So-Armah
Cynthia M So-Armah
MAMaryCatherine E Arbour
MaryCatherine E Arbour
CHChuanchin Huang
Chuanchin Huang
CYChase G Yarbrough
Chase G Yarbrough
Background: Hepatitis C virus (HCV) disproportionately affects racial minorities and socially disadvantaged groups in the United States. Despite highly effective direct-acting antiviral (DAA) therapies, treatment disparities persist. Methods: We conducted a retrospective cohort study using electronic medical record data from both inpatient and outpatient settings in an urban academic medical center between 1 October 2018 and 1 October 2023. Multivariable logistic regression identified sociodemographic and clinical predictors of HCV treatment initiation, defined as a documented direct-acting antiviral prescription, among individuals with positive HCV RNA between 2018 and 2023. Results: Among 4345 individuals, 1150 (26.5%) were prescribed HCV treatment. Black individuals were less likely to be prescribed HCV treatment compared to White individuals (adjusted odds ratio [aOR], 0.68 [95% confidence interval {CI}, .53–.88]). Individuals experiencing homelessness (aOR, 0.57 [95% CI, .46–.69]) and those with Medicaid (aOR, 0.82 [95% CI, .68–.98]) or no insurance (aOR, 0.49 [95% CI, .37–.65]) were also less likely to be prescribed HCV treatment. Individuals with mental health diagnoses (aOR, 1.34 [95% CI, 1.11–1.61]) were more likely to receive HCV treatment. Untreated individuals had a higher percentage of inpatient (12.3%) and emergency department visits (17.7%) than those who received treatment (3.4% and 4.8%, respectively). Conclusions: Significant disparities in HCV treatment initiation were observed, with lower rates among Black individuals, those experiencing homelessness, and individuals with Medicaid or no insurance. These inequities perpetuate a disproportionate burden of liver disease and preventable mortality in already marginalized populations.